Enanta Pharmaceuticals (NASDAQ: ENTA) generates annual revenues primarily through royalty payments derived from worldwide net sales of MAVYRET and MAVIRET, AbbVie's hepatitis C virus treatment. Its trailing twelve-month revenues sit at approximately $69.2 million, with individual quarterly figures fluctuating based on underlying commercial sales reported by AbbVie, such as quarterly revenues of $17.2 million and $14.4 million reported across recent fiscal periods.